Background: Seasonal influenza is an important cause of morbidity and mortality worldwide. Immune activation after stimulation with interferon-gamma leads to increased production of neopterin but also results in increased tryptophan catabolism through indoleamine 2,3-dioxygenase (IDO). Our pilot study determined neopterin serum levels and IDO activity in patients with influenza infection and investigated whether neopterin is linked to clinical outcome parameters (mortality ≤30 days, acute cardiac events (ACE) length of hospitalization, ICU admission).
| INTRODUC TI ON
Seasonal influenza is an important cause of morbidity and mortality worldwide, with an annual incidence rate estimated between 5% and 10% in adults and 20% and 30% in children, resulting in about 290 000-650 000 deaths per year. 1 Especially infants, older adults and patients with chronic illnesses like cardiovascular disease or immunosuppression are at risk. 2, 3 Continuous variations of circulating seasonal influenza virus subtypes, dual or repeated infections during one season and limited effectivity of vaccination are major challenges. [4] [5] [6] The pteridine neopterin is a marker of cell-mediated immune activation, which is biochemically inert and whose half-life in the human organism is mainly affected by renal excretion. [7] [8] [9] Activation of monocytes/macrophages after stimulation with interferon-gamma (IFN-γ) leads to increased production of neopterin. 8, 9 However, activation of the immune system via IFN-γ also results in increased tryptophan catabolism through the kynurenine pathway. Degradation of tryptophan to kynurenine is catalyzed by indoleamine 2,3-dioxygenase (IDO). 10 Indoleamine 2,3-dioxygenase is inducible by pro-inflammatory cytokines, in particular IFN-γ. [11] [12] [13] Increased neopterin levels are observed during viral infections, and previous studies have shown that serum neopterin levels combined with C-reactive protein (CRP) can differentiate between viral and bacterial etiologies in acute respiratory tract infections. [14] [15] [16] Increased levels of neopterin have previously also been associated with adverse outcomes in different diseases including viral infections. 8, [16] [17] [18] Similarly, tryptophan metabolism is able to slow down cellular immune response, for example, during infections, and thus, the determination of tryptophan metabolites may hold promise to predict outcomes in viral infections. 19 Since influenza antigen bed-side tests have limited sensitivity and polymerase chain reaction (PCR)-based methods are expensive and often not available, cheaper and more reliable biomarkers for diagnosis, and risk stratification of patients with influenza infection are desired. 20 The aim of this pilot study was to investigate neopterin levels and IDO activity in sera of hospitalized patients with influenza infection and to analyze correlations with clinical outcome parameters in a small real-life cohort. We also questioned if discrimination between influenza and community-acquired pneumonia (CAP) is possible by assessing neopterin serum levels.
| PATIENTS AND ME THODS

| Subjects
We retrospectively analyzed eligible subjects by reviewing the electronic medical records of patients, who were treated at the These results were compared to a historical cohort of 100 healthy volunteers. 22 The healthy volunteers were recruited from the Central Institute of Blood Transfusion and Immunology of the University Clinics Innsbruck after exclusion of infection or active diseases. The mean age of the cohort was 49 ± 11.4 years, and 42 participants were women. (The demographics of the cohort are described in Table 1 and were published previously 22 ).
To evaluate the discriminative potential of neopterin, we studied neopterin levels in an age-matched historical cohort of 48 patients with CAP. 23 Community-acquired pneumonia patients were included if CAP-related symptoms, typical respiratory auscultation sounds, and a chest x-ray or CT scan confirming a pneumonic infiltrate were present. The cohort consisted of 18 female and 30 male patients, the mean age was 62.75 ± 18.92 years, and all patients needed in-hospital therapy. The exact demographics of the cohort are described elsewhere. 23 
| Statistical analyses
| Ethical approval
| RE SULTS
| Clinical cases
Forty patients were included in this retrospective analysis, and the ratio of influenza A and B was 3: Figure 2 ). When splitting the cohort into patients with either influenza virus type A or B, no significant differences between laboratory parameters were seen (Table 2) . 
| Tryptophan metabolism
Fourteen serum samples of patients with confirmed influenza infection (Flu A: Flu B = 13:1) were identified in our biobank and subsequently analyzed and compared to a healthy historical cohort. The exact details of the control cohort are described elsewhere. 22 The mean concentrations of neopterin, tryptophan, kynurenine, and Kyn/Trp, as well as the demographic details of the sub-cohort, are shown in Table 3 . Overall, we found significantly higher levels of neopterin (P < .01), kynurenine (P < .01), Kyn/Trp (P < .01), and lower levels of tryptophan (P < .01) when comparing influenza patients to healthy controls (Figures 2 and 3) . 
| The discriminative potential of neopterin in the setting of influenza and CAP
To analyze the discriminative potential of neopterin, a cohort of 48 patients with CAP was compared to the influenza patients. 23 The two cohorts were well matched in terms of age, gender, and creatinine levels (Table 1) . Community-acquired pneumonia and WBC concentrations were significantly higher in CAP patients compared to influenza patients (P < .01), whereas neopterin concentrations were significantly lower (P < .01, Table 1, Figure 2 ). Receiver operating characteristic analysis for differentiation between CAP and influenza patients showed the highest AUC for CRP (AUC = 0.849), followed by WBC (AUC = 0.680) and neopterin (AUC = 0.663, Figure 4 ). 
| D ISCUSS I ON
Influenza is an important cause of morbidity and mortality worldwide. Several inflammatory markers, which correlate with disease severity, have intensively been studied in the past.
In our pilot study, we were able to show an elevation of neopterin serum levels at the diagnosis of influenza infection. Moreover, neopterin correlated with prognostic variables, namely the duration of hospitalization, hsTroponinT levels at admission, and acute cardiac events. Also, neopterin levels can discriminate between influenza infection, healthy controls, and CAP; however, CRP and WBC revealed higher AUC.
To date, only very few studies analyzed neopterin in human influenza virus infection. Chang et al described neopterin concentrations in Chinese patients with acute dengue fever infection and compared it to other virus infections like influenza. 16 They showed an elevation of neopterin levels above the upper limit of the norm in all viral infections. However, they found significant differences between the various etiologies with up to threefold higher concentrations in dengue patients when compared to influenza patients. They also showed the potential of neopterin as a prognostic marker in dengue fever infection, as initial levels cor- 
| CON CLUS ION
In summary, we were able to show an elevation of neopterin serum levels as well as a simultaneous induction of IDO as represented by an elevated Kyn/Trp in all patients with influenza virus infection.
Neopterin seems to be related to outcome variables, while in our small cohorts, the performance to differentiate between CAP and influenza was poor. Neopterin might be a valuable biomarker to identify patients at an elevated risk of a worsened outcome; however, further prospective validations studies are needed to support the here presented results.
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